
Standigm
Founded Year
2015Stage
Private Equity | AliveTotal Raised
$78.25MLast Raised
$10M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-22 points in the past 30 days
About Standigm
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
Loading...
Standigm's Product Videos
Standigm's Products & Differentiators
ASK™
Standigm ASK™ focuses on AI-driven drug target identification, integrating knowledge-based and omics-based technologies. ASK-Pathfinder™ predicts target-disease associations using a biomedical knowledge graph. ASK-SCREENER™ extracts disease-target relationships from text. ASK-PWN™ identifies disease-specific targets by applying omics data to a modified PPI network. ASK-GSM™ identifies metabolism-related targets using patient- or disease-specific metabolic models based on transcriptomic data.
Loading...
Research containing Standigm
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Standigm in 1 CB Insights research brief, most recently on Dec 12, 2022.
Expert Collections containing Standigm
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Standigm is included in 5 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Advanced Manufacturing
4,532 items
Companies in the advanced manufacturing tech space, including companies focusing on technologies across R&D, mass production, or sustainability
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI in drug discovery
528 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Artificial Intelligence (AI)
9,151 items
Standigm Patents
Standigm has filed 11 patents.
The 3 most popular patent topics include:
- extrapyramidal and movement disorders
- inflammations
- neurological disorders

Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/14/2017 | Combination drugs, Abandoned drugs, Amines, Prodrugs, Heat shock proteins | Application |
Application Date | 3/14/2017 |
|---|---|
Grant Date | |
Title | |
Related Topics | Combination drugs, Abandoned drugs, Amines, Prodrugs, Heat shock proteins |
Status | Application |
Latest Standigm News
Jun 25, 2025
The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034 ” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, June 25, 2025 / EINPresswire.com / -- The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034 The AI in pharma market size has shown exponential growth in recent years. Current data shows its jump from $2.92 billion in 2024 to an estimated $3.8 billion in 2025 with a compound annual growth rate CAGR of 30.1%. This surge in the historic period can be attributed to the increased adoption of artificial intelligence AI for cost efficient drug discovery and the expanding implementation of AI in radiology. As For The Future, How Is The AI In Pharma Market Anticipated To Grow? The AI in pharma market size is forecasted for substantial growth in the upcoming years. Estimated numbers point towards a growth to $9.64 billion in 2029 at a compound annual growth rate CAGR of 26.2%. Several factors contribute to this upswing in the forecast period, one of which is the adoption of cloud-based applications and services by pharma companies, alongside increasing healthcare expenditure and burgeoning government support for AI development. We also foresee major trends in the forecast period including the introduction of generative AI in pharma, the increasing use of AI in molecular target identification, and the integration of AI in the drug screening process. Other anticipated developments include advancements in AI tools for the pharmaceutical industry, growing investments targeted towards the development of new product solutions, and strategic partnerships and collaborations among market players. Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample_request?id=3887&type=smp What Are The Key Drivers Of The AI In Pharma Market Going Forward? The rising adoption of cloud-based applications and services by pharmaceutical companies is anticipated to fuel the growth of the AI in pharma market. These cloud-based drug discovery platforms utilize cutting-edge research and development capabilities in the pharmaceutical industry. They leverage the potential of data analytics and cloud computing technologies to streamline drug discovery procedures, propelling the efficiency, economy, and collaboration of these processes. Pharmaceutical companies, being significant market participants and end-users of these frameworks, benefit from the secure data storage options these platforms provide, allowing the handling of large volumes of clinical, chemical, biological data. Who Are The Key Industry Players In The Ai In Pharma Market The key players shaping the AI in pharma market include industry giants like Concerto HealthAI, Alphabet Inc., OWKIN, Nvidia Corporation, PathAI, Insilico Medicine, Exscientia, Microsoft Corporation, XtalPi, Intel, Standigm, and Takeda Pharmaceutical Company Ltd. Others include Otsuka Pharmaceutical Co. Ltd., China National Pharmaceutical Group Co. Ltd. Sinopharm, Jiangsu Hengrui Medicine Co. Ltd, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharma, Alliance Pharm Pte Ltd., Shanghai Pharmaceuticals, DeepMind, GlaxoSmithKline, Sanofi, Bayer, Renalytix AI, Merck, AstraZeneca, Iktos, Benevolent AI, Novartis, Ardigen, Botkin, Webiomed, Care Mentor AI, Diagnocat Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report What Are The Emerging Trends In The AI In Pharma Market? In terms of emerging trends, companies in the market are increasingly directing their focus towards the use of generative AI in pharma to improve medical consultations. Generative AI, a subfield of artificial intelligence, creates new data instances that resemble existing data. This technology's introduction into the pharmaceutical industry holds the potential to revolutionize drug discovery and development and medical records management. How Is The AI In Pharma Market Segmented A deep dive into the segmentation of the AI in pharma market reveals the following main sectors: 1 By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning 2 By Drug Type: Small Molecule, Large Molecules 3 By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction Further dissection of these sectors gives rise to subsegments: 1 By Context-Aware Processing: Real-Time Data Processing, Contextual Recommendation Systems, Adaptive Learning Systems 2 By Natural Language Processing NLP: Text Analytics And Sentiment Analysis, Chatbots And Virtual Assistants, Document And Data Mining 3 By Querying Method: Structured Querying, Unstructured Querying, Semantic Search Technologies What Are The Regional Insights Into The AI In Pharma Market? In terms of regional performance, North America held the lion's share in the AI in pharma market in 2024. However, the AI in pharma market report has a global coverage extending to Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa. Browse Through More Similar Reports By The Business Research Company: Pharma Microbiology Testing Kits Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report Pharmaceutical API Manufacturing Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report Pharmacies and Healthcare Stores Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/pharmacies-and-healthcare-stores-global-market-report About The Business Research Company The Business Research Company, with a collection of over 15000+ reports from 27 industries spanning 60+ geographies has built a strong reputation for delivering comprehensive, data-rich research and insights. Powered by 1,500,000 datasets, our in-depth secondary research and unique insights from industry pioneers empowers you with the knowledge necessary to stay ahead in the game. Contact us at: The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info Follow us on: LinkedIn: https://in.linkedin.com/company/the-business-research-company YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Standigm Frequently Asked Questions (FAQ)
When was Standigm founded?
Standigm was founded in 2015.
Where is Standigm's headquarters?
Standigm's headquarters is located at 3rd Floor, Seoul.
What is Standigm's latest funding round?
Standigm's latest funding round is Private Equity.
How much did Standigm raise?
Standigm raised a total of $78.25M.
Who are the investors of Standigm?
Investors of Standigm include Pavilion Capital, SK Chemicals, Kakao Ventures, Atinum Investment, LB Investment and 14 more.
Who are Standigm's competitors?
Competitors of Standigm include Healx, Atomwise, Insilico Medicine, Aitia, Cyclica and 7 more.
What products does Standigm offer?
Standigm's products include ASK™ and 1 more.
Loading...
Compare Standigm to Competitors

Aitia operates as a biotechnology company. It utilizes causal artificial intelligence (AI), multi-omic patient data, and Gemini Digital Twins to study the biological mechanisms of diseases in the oncology and neurodegenerative disease sectors. The company aims to create computational representations of diseases to assist in the development of therapies. It was founded in 2000 and is based in Somerville, Massachusetts.

Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.

Healx focused on drug discovery in the healthcare sector. The company specializes in developing treatments for rare diseases by leveraging artificial intelligence and drug development expertise. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.

Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.
SOM Biotech operates as a clinical-stage drug discovery and development company that focuses on the treatment of rare Central Nervous System disorders. The company utilizes an artificial intelligence platform to discover and develop drugs, with emphasis on orphan diseases and repurposing existing drugs for new therapeutic indications. SOM Biotech's lead product has completed Phase 2b trials for Huntington's Disease. It was founded in 2009 and is based in Barcelona, Spain.
Loading...
